HC Wainwright Reiterates Buy Rating for Aethlon Medical (NASDAQ:AEMD)

HC Wainwright reaffirmed their buy rating on shares of Aethlon Medical (NASDAQ:AEMD) in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the medical equipment provider’s stock. HC Wainwright also issued estimates for Aethlon Medical’s Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.73) EPS and FY2026 earnings at ($0.49) EPS.

Separately, StockNews.com raised shares of Aethlon Medical to a “sell” rating in a research note on Wednesday.

Aethlon Medical Trading Down 4.3 %

AEMD opened at $0.58 on Wednesday. Aethlon Medical has a 12-month low of $0.24 and a 12-month high of $1.85. The firm has a market capitalization of $8.44 million, a PE ratio of -0.37 and a beta of 1.88. The firm has a 50 day moving average of $0.65 and a two-hundred day moving average of $0.49.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. As a group, analysts predict that Aethlon Medical will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Aethlon Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Boothbay Fund Management LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth approximately $186,000. Virtu Financial LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth approximately $81,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter worth approximately $31,000. Allegiance Financial Group Advisory Services LLC acquired a new stake in Aethlon Medical in the 4th quarter valued at $26,000. Finally, Renaissance Technologies LLC acquired a new stake in Aethlon Medical in the 4th quarter valued at $25,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.